Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen, Inc.    AMGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Amgen, Inc. : Amgen : FDA Letter Rejects Expanded Use Of Xgeva For Prostate Cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2012 | 01:22pm CEST

Amgen Inc. (AMGN) received a complete response letter from the U.S. Food and Drug Administration rejecting the expanded use of Xgeva in men with prostate cancer that hasn't spread to the bones.

According to the drug maker, the FDA letter said the agency can't approve the supplemental biologics license application in its present form because the effect on bone metastases-free survival doesn't outweigh the risks, such as osteonecrosis of the jaw, a rare jaw-decay problem.

"We are reviewing the complete response letter and will work with FDA to determine any next steps," said Sean E. Harper, executive vice president of research and development.

Xgeva is currently approved to delay fractures and other bone injuries in patients whose cancer has already spread to the bones. It is also sold under the brand name Prolia as an osteoporosis treatment, but is administered at a lower dose. Xgeva's and Prolia's combined sales in 2011 topped $550 million.

A federal advisory panel in February rejected Amgen's proposal to expand the bone drug's use, saying it was unclear whether the results were clinically meaningful.

Amgen's study of Xgeva in men with prostate cancer that hadn't responded to previous therapies, but hadn't yet spread to the bones showed the drug prolonged median bone metastatis-free survival by 4.2 months.

Shares closed Thursday at $70.79 and were inactive premarket. The stock it up 10% so far this year.

-By Melodie Warner, Dow Jones Newswires; 212-416-2283; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN, INC.
04/24 AMGEN INC. (NASDAQ : AMGN) Files An 8-K Entry into a Material Definitive Agreeme..
04/24 AMGEN INC : Entry into a Material Definitive Agreement, Financial Statements and..
04/24 AMGEN : Health and Human Services Department (HHS); Food and Drug Administration..
04/24 CELGENE CORPORATION (NASDAQ : CELG) Cambridge Expansion Drive Gathers Momentum
04/21 AMGEN : Announces Webcast Of 2017 First Quarter Financial Results
04/18 AMGEN : Launches Neulasta® (pegfilgrastim) Onpro® NARRATIVES
04/06 AMGEN, INC. (NASDAQ : AMGN) Submits sBLA Seeking To Expand XGEVA Label
04/06 AMGEN : Files for Xgeva Label Expansion, To Include Myeloma
04/05 APPLICATION FOR MULTIPLE INDICATIONS : AMGN) To US And Europe Regulators
04/04 AMGEN, INC. (NASDAQ : AMGN) To Move Employees From Headquarters In Restructuring..
More news
Sector news : Bio Therapeutic Drugs
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
04/18DJACTELION : J&J Lifts Forecast on Actelion Tie-Up--Update
04/18DJJOHNSON & JOHNSON : Lifts Forecast on Actelion Tie-Up
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug -- Up..
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
11:59a Money flow surges in biotechs, Novartis aims for more early-stage deals
04/24 Amgen to co-promote migraine med erenumab with Novartis in U.S.
04/24 My 83 Stock Portfolio Review Highlighting Defensive Sectors And My Energy Sto..
04/24 BIOTECH FORUM DAILY DIGEST : Biotech Lags; Revisiting Radius Health
04/24 A Physician Analyzes Valeant's Siliq, As The Stock Crashes
Advertisement
Financials ($)
Sales 2017 23 012 M
EBIT 2017 11 763 M
Net income 2017 8 141 M
Finance 2017 1 113 M
Yield 2017 2,78%
P/E ratio 2017 14,85
P/E ratio 2018 14,43
EV / Sales 2017 5,17x
EV / Sales 2018 4,55x
Capitalization 120 053 M
More Financials
Chart AMGEN, INC.
Duration : Period :
Amgen, Inc. Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Full-screen chart
Technical analysis trends AMGEN, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 186 $
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Chief Financial Officer & Executive Vice President
Sean E. Harper Executive Vice President-Research & Development
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.11.58%120 053
CELGENE CORPORATION6.39%95 807
GILEAD SCIENCES, INC.-7.49%86 604
REGENERON PHARMACEUTIC..0.83%39 455
ACTELION LTD26.98%30 323
VERTEX PHARMACEUTICALS..59.71%29 231
More Results